𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Markers of Bone Turnover for Monitoring Treatment of Osteoporosis with Antiresorptive Drugs

✍ Scribed by P. D. Delmas


Publisher
Springer-Verlag
Year
2000
Tongue
English
Weight
218 KB
Volume
11
Category
Article
ISSN
0937-941X

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Effects of denosumab on bone turnover ma
✍ Richard Eastell; Claus Christiansen; Andreas Grauer; Stepan Kutilek; Cesar Liban πŸ“‚ Article πŸ“… 2011 πŸ› American Society for Bone and Mineral Research 🌐 English βš– 272 KB πŸ‘ 1 views

## Abstract Denosumab, a fully human monoclonal antibody to RANKL, decreases bone remodeling, increases bone density, and reduces fracture risk. This study evaluates the time course and determinants of bone turnover marker (BTM) response during denosumab treatment, the percentage of denosumab‐treat

The potential value of monitoring bone t
✍ Katy JL Bell; Andrew Hayen; Les Irwig; Marc C Hochberg; Kristine E Ensrud; Steve πŸ“‚ Article πŸ“… 2011 πŸ› American Society for Bone and Mineral Research 🌐 English βš– 93 KB

## Abstract Biochemical markers of bone turnover have been proposed to monitor the response to bisphosphonate therapy for osteoporosis, but this requires true between‐person differences in the response to therapy. Using mixed models we analyzed three annual measurements of two markers (bone alkalin